CRIS Current Research Information System

EVANGELISTI, CAMILLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.935
AS - Asia 4.708
EU - Europa 3.991
SA - Sud America 277
AF - Africa 251
OC - Oceania 6
Totale 15.168
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.870
SG - Singapore 1.272
CN - Cina 1.215
VN - Vietnam 1.187
GB - Regno Unito 884
IT - Italia 761
SE - Svezia 571
DE - Germania 532
HK - Hong Kong 326
FR - Francia 238
IN - India 225
RU - Federazione Russa 198
UA - Ucraina 190
BR - Brasile 179
IE - Irlanda 141
KR - Corea 104
FI - Finlandia 102
ZA - Sudafrica 101
JP - Giappone 78
NL - Olanda 74
EE - Estonia 71
JO - Giordania 51
CH - Svizzera 48
CI - Costa d'Avorio 47
TG - Togo 46
BD - Bangladesh 41
AR - Argentina 39
CA - Canada 37
BG - Bulgaria 36
TH - Thailandia 31
AT - Austria 29
PH - Filippine 28
ID - Indonesia 25
BE - Belgio 22
SC - Seychelles 22
PL - Polonia 17
EC - Ecuador 16
ES - Italia 16
MX - Messico 15
PK - Pakistan 14
TR - Turchia 14
IQ - Iraq 13
HR - Croazia 12
TW - Taiwan 12
CL - Cile 11
IR - Iran 11
LT - Lituania 11
SA - Arabia Saudita 11
UZ - Uzbekistan 10
PY - Paraguay 9
PT - Portogallo 8
VE - Venezuela 8
CO - Colombia 7
EG - Egitto 7
LB - Libano 7
AU - Australia 5
IL - Israele 5
MY - Malesia 5
NG - Nigeria 5
AL - Albania 4
AZ - Azerbaigian 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
GR - Grecia 4
MA - Marocco 4
NO - Norvegia 4
NP - Nepal 4
PE - Perù 4
DO - Repubblica Dominicana 3
DZ - Algeria 3
ET - Etiopia 3
JM - Giamaica 3
KE - Kenya 3
KH - Cambogia 3
AE - Emirati Arabi Uniti 2
BY - Bielorussia 2
DK - Danimarca 2
LA - Repubblica Popolare Democratica del Laos 2
PS - Palestinian Territory 2
RS - Serbia 2
SI - Slovenia 2
SN - Senegal 2
TN - Tunisia 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
BO - Bolivia 1
CG - Congo 1
CM - Camerun 1
CY - Cipro 1
GE - Georgia 1
GY - Guiana 1
HN - Honduras 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
Totale 15.160
Salva come PNG Salva come JPEG
Città #
Singapore 854
Southend 739
Ashburn 669
Fairfield 533
Chandler 357
Santa Clara 339
San Jose 312
Hong Kong 308
Woodbridge 293
Houston 283
Ho Chi Minh City 276
Wilmington 265
Bologna 235
Seattle 226
Hanoi 210
Princeton 193
Ann Arbor 191
Hefei 190
Cambridge 187
Dong Ket 159
Dallas 154
Beijing 145
Dublin 141
Boardman 134
Jacksonville 109
Los Angeles 98
Nanjing 92
Lauterbourg 91
Council Bluffs 87
Seoul 85
Helsinki 82
Westminster 80
Padova 78
Tokyo 64
Berlin 57
New York 56
Amman 51
Abidjan 47
Frankfurt am Main 46
Lomé 46
Jinan 43
Turin 41
Saint Petersburg 39
San Diego 39
Changsha 38
Milan 38
Redmond 38
Shenyang 38
Washington 38
Da Nang 35
Haiphong 35
Sofia 35
Bern 34
Bremen 34
Buffalo 33
São Paulo 33
Redondo Beach 30
Shanghai 30
Guangzhou 29
Mülheim 29
Johannesburg 28
Tianjin 25
Nanchang 24
Brussels 20
London 19
Rome 19
Chicago 18
Des Moines 18
Falkenstein 18
Hebei 18
Hải Dương 18
Norwalk 18
Vienna 18
Munich 17
Bengaluru 16
Florence 16
Nuremberg 16
Orem 15
Rimini 15
The Dalles 15
Medford 14
Bangkok 13
Ninh Bình 13
Udine 13
Warsaw 13
Zhengzhou 13
Dearborn 12
Falls Church 12
Haikou 12
Jakarta 12
Lappeenranta 12
Ningbo 12
Toronto 12
Atlanta 11
Hangzhou 11
Jiaxing 11
Montreal 11
Taiyuan 11
Verona 11
Chengdu 10
Totale 9.881
Salva come PNG Salva come JPEG
Nome #
B-all complexity: Is targeted therapy still a valuable approach for pediatric patients? 308
Lamin A and prelamin A counteract invasiveness of osteosarcoma cells 293
Combining prelamin A accumulation and oxidative stress: A strategy to target glioblastoma 271
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting. 261
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235, against T-cell acute lymphoblastic leukemia. 224
Therapeutic targeting of CK2 in acute and chronic leukemias. 222
Improving nelarabine efficacy in T-cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. 213
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. 209
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 206
Phospholipases in Gliomas: Current Knowledge and Future Perspectives from Bench to Bedside 204
Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia 204
Autophagy in acute leukemias: a double-edged sword with important therapeutic implications. 201
The wide and growing range of lamin B‑related diseases: from laminopathies to cancer 199
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 197
Intranuclear 3'-phosphoinositide metabolism and Akt signaling: New mechanisms for tumorigenesis and protection against apoptosis? 196
Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. 193
Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells. 192
Emerging Roles of Phospholipase C Beta Isozymes as Potential Biomarkers in Cardiac Disorders 192
A COMBINATION OF BORTEZOMIB WITH CX-4945, A CASEIN KINASE 2 (CK2) INHIBITOR, HAS SYNERGISTIC CYTOTOXIC EFFECTS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) CELL LINES 191
Nuclear diacylglycerol kinase-theta is activated in response to nerve growth factor stimulations of PC12 cells 184
Cutting edge: the role of mTOR signaling in laminopathies. 183
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. 180
Signaling Role of Pericytes in Vascular Health and Tissue Homeostasis 179
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 179
Targeting Wnt/beta-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. 178
Pathobiology and therapeutic relevance of GSK-3 in chronic hematological malignancies. 177
GSK-3: a multifaceted player in acute leukemias. 177
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. 175
Nuclear protein kinase C 173
Advances in Targeting Signal Transduction Pathways. 173
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. 172
Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy 171
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling 171
Nuclear inositol lipid metabolism: more than just second messenger generation? 171
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival er chaperone BIP/GRP78 and turning on the pro-apoptotic NF-κB. 171
The involvement of signaling pathways in the pathogenesis of osteoarthritis: An update 169
Therapeutic targeting of polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblstic leukemia. 167
The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. 167
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies 163
ASSESSMENT OF THE EFFECT OF SPHINGOSINE KINASE INHIBITORS ON APOPTOSIS, UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY OF T-ACUTE LYMPHOBLASTIC LEUKEMIA CELLS: INDICATIONS FOR NOVEL THERAPEUTICS 163
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. 162
The emerging multiple roles of nuclear Akt. 160
Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. 159
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia 159
Nuclear phosphoinositides and their roles in cell biology and disease. 158
Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. 157
Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta. 156
Nuclear diacylglycerol kinase-{zeta} is a negative regulator of cell cycle progression in C2C12 mouse myoblasts 152
Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias 152
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. 152
Desmin and Plectin Recruitment to the Nucleus and Nuclei Orientation Are Lost in Emery-Dreifuss Muscular Dystrophy Myoblasts Subjected to Mechanical Stimulation 151
The PI3K/Akt/mTOR Pathway 151
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells 151
The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis 147
New advances in targeting aberrant signaling pathways in T-cell Acute Lymphoblastic Leukemia. 146
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myeloid leukemia cells. 145
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. 145
TIS2/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest 140
Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update. 140
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance 139
The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML) 138
Subnuclear localization and differentiation-dependent increased expression of DGK-zeta in C2C12 mouse myoblasts. 137
Nuclear expression of diacylglycerol kinases: possible involvement in DNA replication. 135
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. 134
GSK-3β: a key regulator of breast cancer drug resistance 133
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. 133
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance 130
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. 129
Targeting the cancer initiating cell: the ultimate target for cancer therapy. 129
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. 128
Intranuclear 3'-phosphoinositide metabolism and apoptosis protection in PC12 cells 127
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer. 125
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. 124
The emerging role of the phosphatidylinositol 3-kinase/Akt/mTOR signaling network in normal myelopoieis and leukemogenesis. 124
Nuclear diacylglycerol kinases: emerging downstream regulators in cell signaling networks 124
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. 124
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. 120
PI3K isoforms inhibition associated with anti BCR-ABL1 drugs shows in vitro increased anti-leukemic activity in B-pre acute lymphoblastic leukemia. 119
The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion 119
New agents and approaches for targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cell survival pathways. 118
The role played by Wnt/beta-catenin signaling pathway in acute lymphoblastic leukemia. 117
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. 115
DGKζ is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. 115
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. 113
Nuclear phosphoinositide specific phospholipase C (PI-PLC)-ss1: a central intermediary in nuclear lipid-dependent signal transduction 110
PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy 106
Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance 105
The unfolded protein response: a novel therapeutic target in acute leukemias. 102
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. 98
INHIBITION OF CLASS I PHOSPHATIDYLINOSITOL 3-KINASES (PI3KS) ISOFORMS IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL): WHICH IS THE BEST THERAPEUTIC STRATEGY? 97
Elevated tgf b2 serum levels in emery-dreifuss muscular dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 97
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. 96
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia 95
Morphological and biochemical patterns in skeletal muscle apoptosis. 94
Defective collagen VI-NG2 axis impairs pericyte balance between proliferation and quiescence in COLVI-related myopathies 88
null 86
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients 81
null 69
Drug enteric metabolism in gut microbiota-brain crosstalk 63
null 62
Totale 15.300
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.651
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.651
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021311 0 0 0 0 0 0 0 0 0 0 0 311
2021/20221.894 200 38 135 134 151 103 36 133 51 287 336 290
2022/20231.701 173 215 81 244 119 130 76 105 297 25 155 81
2023/2024617 37 67 74 51 95 173 18 22 18 29 21 12
2024/20251.975 42 176 163 150 495 133 132 76 23 88 94 403
2025/20265.048 399 599 521 353 576 300 487 169 919 386 201 138
Totale 15.457